Results 131 to 138 of about 1,869 (138)

Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021

Morbidity and Mortality Weekly Report, 2021
Nicholas M Mohr, David A Talan, Karisa K Harland   +2 more
exaly  

Adverse Effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 Vaccines among the Adult Population in Saudi Arabia: A Cross-Sectional Study

Vaccines, 2023
Sultan Ayoub Meo
exaly  

Graded Administration of Second Dose of Moderna and Pfizer-BioNTech COVID-19 mRNA Vaccine in Patients with Hypersensitivity to First Dose

Open Forum Infectious Diseases, 2021
Peter Capucilli, Allison Ramsey, Edward E Walsh   +2 more
exaly  

COVID-19: Perceived Infection Risk and Barriers to Uptake of Pfizer-BioNTech and Moderna Vaccines Among Community Healthcare Workers

Journal of Racial and Ethnic Health Disparities, 2021
Tolulope B Famuyiro, Mukaila A Raji
exaly  

ModeRNA: a tool for comparative modeling of RNA 3D structure

Nucleic Acids Research, 2011
Tomasz Puton, Janusz M Bujnicki
exaly  

Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021

Morbidity and Mortality Weekly Report, 2021
exaly  

Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees

Clinical Infectious Diseases, 2022
exaly  

ModeRNA server: an online tool for modeling RNA 3D structures

Bioinformatics, 2011
Kaja Milanowska, Tomasz Puton, Janusz M Bujnicki   +2 more
exaly